HONG KONG (Reuters) - A new anti-viral drug to treat both bird and human flu, developed by U.S.-based BioCryst Pharmaceuticals, will be tested across Asia next month, the pharmacist involved in the trial in Hong Kong said on Monday.In an earlier animal trial, the drug, peramivir, boosted the survival rates of mice and ferrets infected with the H5N1 bird flu virus. Some experts say it could be the next-line drug to fight all types of influenza, including H5N1.>>> Discuss This Story
